We evaluated the intensity of HER2 expression in the primary tumor to assess whether such phenomenon be explained by the heterogeneity of the primary tumor and, consequently, the appearance of a minor subpopulation of HER2+ CTCs in the bloodstream (Fig. 3). This evidence concerns the gene ERBB2 and neoplasm.